Therapy-related myeloid neoplasms following peptide receptor radionuclide therapy for neuroendocrine neoplasms: case series reporting characteristics and outcomes from single-centre experience
Endocrine Oncology · 01.01.2026 · 6 (1)
DOI: 10.1530/eo-25-0107 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Oncology, online erschienen am 20.03.2026. Verfasst von Wallace Chow und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTATATE is increasingly used in the treatment of metastatic neuroendocrine neoplasms (NENs). Marrow toxicity resulting in therapy-related myeloid neoplasms (t-MNs) remains a rare but fatal complication of PRRT, with a limited understanding of prognostic or predictive factors.
Methods
We conducted a single-centre retrospective review of all patients with metastatic NEN who received at least one cycle of PRRT and subsequently developed t-MN confirmed on bone marrow biopsy.
Results
Thirteen out of 306 patients (4.2%) developed t-MN during follow-up, confirmed on bone marrow biopsy. The median time from cycle 1 of PRRT to diagnosis of t-MN was 48.3 months (range: 5.4–110.1 months). The median number of PRRT cycles was 4 (range: 3–8). Nine (69%) patients received concomitant radiosensitising chemotherapy with capecitabine, and one (7.7%) had the combination of capecitabine and temozolomide. The median overall survival from cycle 1 of PRRT was 61.9 months (range: 18.5–112.2 months). The median overall survival from diagnosis of t-MN was 10.4 months (range: 1.9–89.3 months). An unfavourable karyotype, a higher degree of cytopaenia and a higher blast percentage in bone marrow were associated with worse survival outcomes of t-MN. Conclusions t-MN following PRRT is an uncommon but serious complication that can occur several years after treatment. This case series highlights the poor prognosis following t-MN diagnosis, particularly if untreated. PRRT is an effective treatment modality for NEN, but prospective studies are needed to explore factors predictive of t-MN development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
- Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
- Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.
- Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
ORCID-Profile: Wallace Chow, David L Chan
Zitieren
APA
Chow, W., Wen, I., Mok, C., Huang, K., Stevenson, W., Roach, P. J., Bailey, D. L., Diakos, C. I., Clarke, S. J., Pavlakis, N., & Chan, D. L. (2026). Therapy-related myeloid neoplasms following peptide receptor radionuclide therapy for neuroendocrine neoplasms: case series reporting characteristics and outcomes from single-centre experience. Endocrine Oncology, 6(1). https://doi.org/10.1530/eo-25-0107
Vancouver
Chow W, Wen I, Mok C, Huang K, Stevenson W, Roach PJ, et al. Therapy-related myeloid neoplasms following peptide receptor radionuclide therapy for neuroendocrine neoplasms: case series reporting characteristics and outcomes from single-centre experience. Endocrine Oncology. 2026;6(1). doi:10.1530/eo-25-0107
BibTeX
@article{Chow2026,
author = {Chow, Wallace and Wen, Ivy and Mok, Claire and Huang, Kathryn and Stevenson, William and Roach, Paul J and Bailey, Dale L and Diakos, Connie I and Clarke, Stephen J and Pavlakis, Nick and Chan, David L},
title = {Therapy-related myeloid neoplasms following peptide receptor radionuclide therapy for neuroendocrine neoplasms: case series reporting characteristics and outcomes from single-centre experience},
journal = {Endocrine Oncology},
year = {2026},
volume = {6},
number = {1},
doi = {10.1530/eo-25-0107}
}
EUVIMED